MedTrace Logo

Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection

NCT02537158 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2016-03-15

No results posted yet for this study

Summary

This study is a prospective non-randomized controlled study. The purpose of this study is to evaluate the validity and safety of sorafenib and transcatheter arterial chemoembolization (TACE) for microvascular invasion (MVI) in hepatocellular carcinoma (HCC) patients after radical surgery.

Conditions

Interventions

DRUG

Sorafenib

sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).

PROCEDURE

TACE

TACE group patients will accept TACE therapy once at a month after resection.

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Xinyu Bi, Doctor · Cancer Hospital and Institute, Chinese Academy of Medical Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02537158 on ClinicalTrials.gov